RT Journal Article
SR Electronic
T1 Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 — January 2023
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.02.23286561
DO 10.1101/2023.03.02.23286561
A1 Poukka, Eero
A1 Goebeler, Sirkka
A1 Nohynek, Hanna
A1 Leino, Tuija
A1 Baum, Ulrike
YR 2023
UL http://medrxiv.org/content/early/2023/03/05/2023.03.02.23286561.abstract
AB Bivalent COVID-19 vaccines were introduced in 2022 but knowledge of how their effectiveness against severe COVID-19 outcomes is sustained over time is currently limited. In Finnish register-based cohort analyses, we compared the risk of severe COVID-19 outcomes among those who received bivalent vaccination (exposed) between 1 September 2022 and 31 January 2023 to those who did not (unexposed). Among elderly aged 65–120 years, bivalent vaccination reduced the risk of hospitalisation and death due to COVID-19. Among the elderly the hazard ratios comparing exposed and unexposed ranged from 0.36 to 0.43 during the first 14–30 days since bivalent vaccination but signs of waning were observed as soon as two months after vaccination. Among the chronically ill aged 18–64 years bivalent vaccination did not reduce the risk of severe COVID-19 outcomes. These results are crucial for further developing COVID-19 vaccination programme worldwide.Competing Interest StatementHanna Nohynek is a member of Finnish National Immunization Technical Advisory Groups and chairman of Strategic Advisory Group of Experts on Immunization for World Health Organization.Funding StatementEero Poukka received a grant from The Finnish Medical Foundation. No other sources of external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:By Finnish law, the Finnish Institute for Health and Welfare (THL) is the national expert institution to carry out surveillance on the impact of vaccinations in Finland (Communicable Diseases Act, https://www.finlex.fi/en/laki/kaannokset/2016/en20161227.pdf). Neither specific ethical approval of this study nor informed consent from the participants was needed. The supplements material includes THL Director of the Department for Health Security signatured statement considering the ethical review.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesBy Finnish law, the authors are not permitted to share individual-level register data. The computing code is available upon request.